Ipamorelin is a synthetic pentapeptide agonist of the ghrelin receptor GHS-R1a (growth hormone secretagogue receptor type 1a), with the reported sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 (CAS 170851-70-4; molecular weight near 711.85 Da). It triggers pulsatile growth hormone (GH) release from anterior pituitary somatotrophs and is distinguished within the secretagogue family by published evidence of selectivity for GH release over ACTH and cortisol responses. It contains non-natural amino acids that improve resistance to proteolytic breakdown. This guide summarizes receptor pharmacology, the published selectivity record, assay-design considerations, and analytical quality points; ipamorelin here is a laboratory research material only, not approved for human or veterinary administration, diagnosis, prevention, or treatment of any condition.
Molecular Identity
Ipamorelin’s structure uses alpha-aminoisobutyric acid (Aib) and D-2-naphthylalanine (D-2-Nal), plus C-terminal amidation; these features shape both receptor fit and metabolic stability. Product documentation lists ≥98% HPLC purity, white lyophilized appearance, solubility in aqueous solvents, and frozen dry storage away from light [3]. Researchers reviewing a batch should confirm sequence, amidation, net peptide content, and salt form rather than relying on the trade name alone.
Mechanism: Gq-Calcium Signaling
GHS-R1a is a constitutively active Gq/11-coupled receptor expressed on pituitary somatotrophs and hypothalamic nuclei. Ipamorelin binding activates phospholipase C, producing IP3 and diacylglycerol; IP3 mobilizes intracellular calcium and drives GH granule exocytosis [2]. This route differs from GHRH analogs such as CJC-1295 No DAC, which use GHRHR and Gs-cAMP signaling. Secretagogue reviews describe the two arms as complementary in co-stimulation models, with endogenous feedback modulation retained because GH secretion remains pulsatile rather than continuously clamped [2].
The Selectivity Evidence
The foundational selectivity study compared ipamorelin with GHRH and reported that ipamorelin did not raise ACTH or cortisol beyond GHRH-control levels even at doses more than 200-fold above the ED50 for GH release; the authors characterized it as the first GHRP-receptor agonist with GH-release selectivity similar to GHRH [1]. That observation matters experimentally: it reduces but does not eliminate the need to measure cortisol, prolactin, and appetite-related readouts in a well-controlled endocrine panel. Later reviews of secretagogues in body-composition research place ipamorelin within the ghrelin-mimetic class while noting that human clinical-program size remains limited and most quantitative evidence comes from receptor assays, animal models, and short human challenge studies [2].
Assay Design and Reported Parameters
For in vitro work, receptor or cell-line assays report ipamorelin GHS-R1a activation in the low-nanomolar range (product references list an approximate EC50 of 0.5-2 nM for receptor assays; treat this as assay-dependent literature context, not a universal constant). Typical controls include a GHS-R1a antagonist arm, vehicle, and a reference secretagogue; culture medium should be refreshed on a schedule matched to proteolytic stability, and solutions filter-sterilized for cell work. In vivo or animal-model sampling should pair early GH pulse measurements with later IGF-1; reported numerical values in vendor or protocol tables derive from specific studies and are not a regimen recommendation for any other setting.
Stability, QC, and Handling
Because the non-natural residues confer improved stability relative to unmodified peptides, ipamorelin handling still follows standard lyophilized-peptide practice: verify CoA for sequence identity, HPLC purity, mass spectrometry molecular weight and amidation confirmation, amino-acid composition, endotoxin, residual solvents, and water content; reconstitute aseptically; aliquot against freeze-thaw loss; store powder frozen and dry; and follow the lot CoA for reconstituted-solution shelf life. Chiral or configuration checks for the D-amino acid are worth requesting where identity ambiguity exists across suppliers.
Safety and Evidence Boundaries
Reported acute considerations across the secretagogue class include injection-site reactions, flushing, transient headaches, nausea, possible water-retention signals, and glucose-related monitoring in endocrine panels. Ipamorelin’s selectivity profile addresses ACTH/cortisol elevation but not every conceivable safety question; chronic-use evidence outside controlled studies remains limited. Anti-doping authorities classify GH secretagogues as prohibited in sport, and all institutional biosafety, animal-care, and ethics requirements apply. No disease-treatment claim, dosing regimen, or self-administration guidance should be drawn from this guide.
Frequently Asked Questions
Q1: What receptor does ipamorelin activate?
The ghrelin receptor GHS-R1a (Gq/11-coupled) on pituitary somatotrophs and hypothalamic neurons, triggering calcium-mediated GH release [1][2].
Q2: What makes ipamorelin selective?
A foundational study found little ACTH/cortisol elevation even at more than 200 times the GH-release ED50, unlike broader first-generation secretagogues [1].
Q3: How does it compare with GHRH analogs?
Ipamorelin uses GHS-R1a/Gq signaling; GHRH analogs use GHRHR/Gs-cAMP; published models test the pathways together for complementary GH release.
Q4: What is its sequence and molecular weight?
Reported sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2; CAS 170851-70-4; approximate molecular weight 711.85 Da [3].
Q5: What EC50 values appear in assay literature?
Receptor-assay references commonly cite a low-nanomolar range (approximately 0.5-2 nM), assay-dependent; confirm in the chosen model rather than treating it as fixed.
Q6: What QC checks matter most?
Sequence and amidation identity, intact mass, HPLC purity, net peptide content, endotoxin, residual solvents, and signed batch CoA traceability.
Q7: Is ipamorelin approved for human use?
No. It is a research-stage secretagogue with a limited controlled human evidence record; the catalog material is for laboratory research only.
Research Material CTA
View the product entry: Ipamorelin · compare CJC-1295 No DAC Batch-level HPLC purity reporting, lab-tested CoA documentation, and worldwide tracked shipping for qualified research buyers. Research use only; verify the current lot certificate before any assay.
Sources
- Ipamorelin, the first selective growth hormone secretagogue. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Beyond the androgen receptor: growth hormone secretagogues in body-composition research (review). https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/
- Product page identity and handling parameters (lot-specific CoA governs). https://hanpropeptides.com/product/ipamorelin/
The Ipamorelin compound data file collects the sequence, molecular weight, CAS and the impurity routes worth watching for this compound on one page.
